Novus Therapeutics, Inc. (NASDAQ:NVUS) is reporting third quarter earnings results on Monday 16th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 1.75 per share.
For the full year, analysts predict loss of $ 14.4 per share.
Stock Performance
On Friday, shares of Novus Therapeutics, Inc. has traded high as $ 21.50 and has cracked $ 20.05 on the downward trend, reaching $ 21.26 with volume of 13.10 thousand shares.
According to the previous trading day, closing price of $ 21.26, representing a 344.00 % increase from the 52 week low of $ 4.50 and a 26.87 % decrease over the 52 week high of $ 27.32.
The company has a market capital of $ 26.63 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Novus Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 16th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 877-407-3982 or 201-493-6780 Outside U.S., with passcode : 13713171 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website novustherapeutics.com
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities.
